Log In
BCIQ
Print this Print this
 

DP-VPA

Also known as: SPD 421

  Manage Alerts
Collapse Summary General Information
Company D-Pharm Ltd.
DescriptionPhospholipid derivative of valproic acid formulated with D-Pharm's Regulated Activation of Prodrugs (RAP) technology
Molecular Target Histone deacetylase (HDAC)
Mechanism of ActionHistone deacetylase (HDAC) inhibitor
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$2.4M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/28/2012

Undisclosed

Undisclosed

Undisclosed

05/31/2011

Undisclosed

$2.4M

Undisclosed

Get a free BioCentury trial today